Chinese Medical E-ournals Database

Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition) ›› 2011, Vol. 07 ›› Issue (05): 476 -480. doi: 10.3877/cma.j.issn.1673-5250.2011.05.020

Review

Research Progress of 1-Deamino-8-D-Arginine-Vasopressin in the Treatment of Patients With Hemophilia

Song-ting BAI, Guang-yao SHENG   

  1. Department of Pediatrics, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
  • Published:2011-10-01
  • Supported by:
    * Project No. 200801004, supported by the Science and Technical Project of the Ministry of Health

1-deamino-8-D-arginine-vasopressin (DDAVP) is a synthetic compound of the antidiuretic hormone vasopressin, which can increase plasma concentration of factor Ⅷ (FⅧ), von Willebrand factor (vWF), and tissue plasminogen activator (t-PA) in normal subjects and patients with hemophilia A(HA). It has been using for the treatment or prevention of bleeding episodes caused by mild HA and type 1 von Willebrand disease (vWD) over the past 30 years on aboard. More and more studies have demonstrated the clinical efficacy of DDAVP for carriers of female HA, patients of HA with inhibitors and acquired HA, even for patients with haemophilia B(HB). DDAVP is safe, cheap and carries no risk of transmitting of blood-borne viral infections particularly during the human immunodeficiency virus (HIV) and hepatitis virus, and developing inhibitor antibodies upon repeated treatments with FⅧ concentrates. Thus, in every patient with newly diagnosed as hemophilia, a test infusion/injection of DDAVP should be carried out to assess the future usefulness of the compound.

1 Castaman G. Desmopressin for the treatment of haemophilia [J]. Haemophilia, 2008, 14(Suppl 1): 15-20.
2 Castaman G, Mancuso ME, Giacomelli SH, et al. Molecular and phenotypic determinants of response to desmopressin in adult patients with mild hemophilia A[J]. J Thromb Hemost, 2009,7:1824-1831.
3 Kaufmann JE, Oksche A, Wollllheim CB, et al. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP[J]. J Clin Invest, 2000, 106:107-116.
4 Federici AB. The use of desmopressin in von Willebrand disease:The experience of the first 30 years(1977-2007)[J]. Haemophilia, 2008, 14(Suppl 1):5-14.
5 Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A[J]. Blood Coagul Fibrinolysis, 2010, 21(7):615-619.
6 Lethagen S, Harris AS, Nilsson IM. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I[J]. Blut, 1990, 60: 187-191.
7 Rodeghiero F, Castaman G, DiBona E, et al. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand' s disease and hemophilia A [ J]. Blood, 1989, 74: 1997-2000.
8 Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP) [J]. Br J Haematol, 1992, 82: 87-93.
9 Ozgonenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin [J]? Postgrad Med J, 2007, 83(977):159-163.
10 Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with hemophilia [J]. Br J Hematol, 2010, 148:522-533.
11 Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A [ J]. J Thromb Hemost, 2010, 8(3): 421-432.
12 Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A[J]. Blood Coagul Fibrinolysis, 2010, 21(7):615-619.
13 Lethagen S. Desmopressin in mild hemophilia A: Indications, limitations, efficacy, and safety [J]. Semin Thromb Hemost, 2003, 29: 101-106.
14 Castaman G, Mancuso ME, Giacomelli SH, et al. Molecular and phenotypic determinants of response to desmopressin in adult patients with mild hemophilia A[J]. J Thromb Haemost, 2009, 7: 1824-1831.
15 Riccardi F, Rivolta GF, Franchini M, et al. Characterization of a novel mutation in the F8 promoter region associated with mild hemophilia A and resistance to DDAVP therapy[J]. J Thromb Haemost, 2009, 7: 1234-1235.
16 De la Fuente B, Kasper CK, Rickles FR, et al. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin [J]. Ann Intern Med, 1985, 103: 6-14.
17 Leissinger C, Becton D, Cornell C, et al. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A[J]. Haemophilia, 2001, 7: 258-266.
18 Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor Ⅷ-deficient women [J]. Blood, 2005, 105:3382.
19 Nolan B, White B, Smith J, O'Reilly C, et al. Desmopressin: Therapeutic limitations in children and adults with inherited coagulation disorders[J]. Br J Haematol, 2000, 109: 865-869.
20 Revel-Vilk S, Blanchette V, Sparling C, et al. DDAVP challenge tests in boys with mild/moderate haemophilia A [J]. Br J Haematol, 2002, 117: 947-951.
21 Sharathkumar A, Lillicrap D, Blanchette VS, et al. Intensive exposure to factor Ⅷ is a risk factor for inhibitor development in mild hemophilia A[J]. J Thromb Haemost, 2003, 1: 1228-1236.
22 Shima M. Diagnosis and treatment of acquired hemophilia [J]. Rinsho Ketsueki, 2010, 51: 1531-1538.
23 Ehl S, Severin T, Sutor HS. DDAVP (desmopressin; 1-deaminocys-8-d-arginine-vasopressin) treatment in children with haemophilia B[J]. Br J Haematol, 2000, 111: 1260-1262.
24 Federici AB. The use of desmopressin in von Willebrand disease:The experience of the first 30 years(1977-2007)[J]. Haemophilia, 2008, 14(Suppl 1): 5-14.
25 Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (vWD): Results from the European Study MCMDM-1 vWD[J]. Blood, 2008, 111(7): 3531-3539.
26 Castaman G, Eikenboom JCJ, Rodeghiero F, et al. A novel candidate mutation (Arg 611→His) in type 1 "platelet discordant" von Willebrand's disease with desmopressin-induced thrombocytopenia [J]. Br J Haematol, 1995, 89: 656-659.
27 Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: Data from an international registry [J]. Thromb Haemost, 2000, 84: 345-349.
[1] Peng Yuan. Advancement of HER-2 positive breast cancer treatment in 2023[J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(02): 66-70.
[2] Shengrui Wang, Guorui Cao, Honglue Tan. Research progress on prevention and treatment of nausea and vomiting after joint replacement[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2024, 18(01): 131-136.
[3] The Joint Surgery Branch of the Chinese Orthopedic Association, Guangdong’s Medical Association of Osteoporosis And Bone Mineral Research, Foshan Shunde 3rd Peoele’s Hospital. Clinical intervention guideline for using of anti-osteoporosis drugs in postoperative fragile hip fractures in China (2023 Edition)[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 751-764.
[4] Lin Yang, Rutie Yin. Current research status on etiology and treatment of patients with white lesions of vulva[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(02): 157-165.
[5] Zeying Jiang, Anting Wang, Jiaoli Wang, Ci Chen, Qiuling Zhou, Yanjuan Huang, Fang Zhou, Yan Xue, Jianfeng Zhou, Wenyong Tan, Meifang Du. Effect of multiple plant oils combination in preventing the chemoradiotherapy induced toxicities[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(06): 523-527.
[6] Changying Ye, Jing Xie, Guicong Ding. Research advances in interim treatment of deciduous tooth caries[J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(05): 365-370.
[7] Shaohua Qu, Yedong Hu, Xiuhao Zhao, Wenna Li, Pengcheng Xiang, Zitian Xiao, Qiming Ma, Junyi Han. Effects of medical versus surgical therapy on ineffective esophageal motility in patients with gastroesophageal reflux diseases[J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(01): 23-28.
[8] Bitao Wang, Zheng Wang, Guobin Wang. Treatment status and progress of Lynch syndrome[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 332-335.
[9] Chengren Zhang, Xiongfei Yang, Binbin Du, Lili Liu, Jingjing Li, Chengzhang Zhu, Dewang Wu, Yaochun Lv. A meta-analysis of primary tumor resection in asymptomatic colorectal cancer with unresectable metastases[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 305-310.
[10] Kaifeng Qiu, Zeyuan Wang, Zhichao He, Kaili Fu, Tonglin Mei, Yingjie Guan, Fei Gao, Junyan Wu. Application of artificial intelligence technology in evidence-based off-label drug use[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(12): 1212-1218.
[11] Junwei Gao, Gaolin Liu. Drug therapies for autoimmune diseases[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(12): 1209-1211.
[12] Qiuyi Chen, Xi Lin, Zhenyin Liu. Advances in the molecular mechanism of lymphatic malformations[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(04): 374-379.
[13] Chunyuan Luo, Hangxin Liu, Yue Li, Yanmei Mai, Lingbo Shi. Postpartum acquired hemophilia A: a case report and review of the literature[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(02): 114-117.
[14] Ruifang Hu, Lijuan Fan. Research progress on diagnostic biomarkers of esophageal squamous intraepithelial neoplasia and status of non-endoscopic treatment[J]. Chinese Journal of Diagnostics(Electronic Edition), 2024, 12(04): 281-286.
[15] Xiaoxiao Zhao, Jiating Qiu, Yishu Zhang, Rong Zhang, Peng Zhang, Xiaolei Liu. Application and prospect of Butylphthalide in the treatment of cognitive impairment[J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2024, 18(01): 19-26.
Viewed
Full text


Abstract